Published in

Kachestvennaya klinicheskaya praktika, 4S, p. 39-46, 2020

DOI: 10.37489/2588-0519-2020-s4-39-46

Links

Tools

Export citation

Search in Google Scholar

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis

Journal article published in 2020 by V. M. Tsvetov ORCID, I. N. Sychev ORCID, D. A. Sychev ORCID
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks.